scholarly journals Homolateral symptoms in brain tumors.

2021 ◽  
Vol 43 (6) ◽  
pp. 58-59
Author(s):  
S. A. Grinberg
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Fluid Systems ◽  
Different Origin ◽  
Supratentorial Tumors

Homolateral symptoms in brain tumors have been described by a number of authors.LB Litvak believes that homolateral symptoms in supratentorial tumors can have a different origin. They can be associated with the dislocation and occlusion of the cerebrospinal fluid systems.

scholarly journals Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Geetika Nehra ◽  
Shannon Andrews ◽  
Joan Rettig ◽  
Michael N. Gould ◽  
Jill D. Haag ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Nasal Mucosa ◽  
Brain Cancer ◽  
Intranasal Administration ◽  
High Performance ◽  
Early Stage ◽  
Plasma Concentrations ◽  
Perillyl Alcohol ◽  
Systemic Absorption

AbstractPerillyl alcohol (POH) has been extensively studied for the treatment of peripheral and primary brain tumors. The intranasal route of administration has been preferred for dosing POH in early-stage clinical trials associated with promising outcomes in primary brain cancer. However, it is unclear how intranasal POH targets brain tumors in these patients. Multiple studies indicate that intranasally applied large molecules may enter the brain and cerebrospinal fluid (CSF) through direct olfactory and trigeminal nerve-associated pathways originating in the nasal mucosa that bypass the blood–brain barrier. It is unknown whether POH, a small molecule subject to extensive nasal metabolism and systemic absorption, may also undergo direct transport to brain or CSF from the nasal mucosa. Here, we compared CSF and plasma concentrations of POH and its metabolite, perillic acid (PA), following intranasal or intravascular POH application. Samples were collected over 70 min and assayed by high-performance liquid chromatography. Intranasal administration resulted in tenfold higher CSF-to-plasma ratios for POH and tenfold higher CSF levels for PA compared to equal dose intravascular administration. Our preclinical results demonstrate POH undergoes direct transport from the nasal mucosa to the CSF, a finding with potential significance for its efficacy as an intranasal chemotherapeutic for brain cancer.

Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors

1976 ◽  
Vol 8 (2) ◽  
pp. 127-141 ◽  
Author(s):  
Remo Fumagalli ◽  
Stefano Pezzotta ◽  
Anna R. Racca ◽  
Pietro Paoletti
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Human Brain ◽  
Human Brain Tumors

scholarly journals Identification of Tumor-Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors

2003 ◽  
Vol 62 (8) ◽  
pp. 855-862 ◽  
Author(s):  
Ping-Pin Zheng ◽  
Theo M. Luider ◽  
Rob Pieters ◽  
Cees J.J. Avezaat ◽  
Martin J. van den Bent ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Proteomic Analysis ◽  
Primary Brain Tumors ◽  
Related Proteins

Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors

2018 ◽  
Vol 56 (6) ◽  
pp. 869-879 ◽  
Author(s):  
Alena Kopkova ◽  
Jiri Sana ◽  
Pavel Fadrus ◽  
Ondrej Slaby
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Communication Channel ◽  
Predictive Biomarkers ◽  
Waste Products ◽  
Diagnostic Biomarkers ◽  
Circulating Micrornas ◽  
The Central Nervous System ◽  
Non Coding Rnas ◽  
Extracellular Environment

Abstract Cerebrospinal fluid (CSF) is a body fluid that has many important functions and is in direct contact with the extracellular environment of the central nervous system (CNS). CSF serves as both the communication channel allowing the distribution of various substances among the CNS cells and the storage facility for the waste products these cells release. For these reasons, CSF is a potential source of diagnostic biomarkers of many CNS diseases, including brain tumors. Recent studies have revealed that CSF also contains circulating microRNAs (miRNAs), short non-coding RNAs that have been described as biomarkers in many cancers. However, CSF miRNAs are difficult to detect, which is why researchers face major challenges, including technological difficulties in its detection and its lack of standardization. Therefore, this review aims (i) to highlight the potential of CSF miRNAs as diagnostic, prognostic and predictive biomarkers in brain tumors, and (ii) to summarize technological approaches for detection of CSF miRNAs.

scholarly journals Clinical Experience with Frameless Neuronavigation Guided Biopsy for Intracranial Space Occupying Lesion

2019 ◽  
Vol 16 (1) ◽  
pp. 25-28
Author(s):  
Suraj Thulung ◽  
Suresh Bishokarma ◽  
Subash Lohani ◽  
Dinuj Shrestha ◽  
Binit Aryal ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Neurological Deficit ◽  
Complication Rate ◽  
Diagnostic Yield ◽  
P Value ◽  
Tumor Diameter ◽  
High Diagnostic Yield ◽  
Guided Biopsy ◽  
Supratentorial Tumors ◽  
Space Occupying Lesion

Biopsy is mandatory for histological diagnosis of non-resectable brain tumors. Of various techniques, neuronavigation guided biopsy provides intraoperative real-time reference and allows biopsy from multiple trajectories. The aim of this study is to assess the efficacy and accuracy of frameless neuronavigation biopsy. We retrospectively reviewed the medical archives of patients with intracranial space occupying lesion who underwent frameless neuronavigation biopsy at our institute between 2016 to 2018. All operations were performed under general anesthesia. Data were analyzed by SPSS version 20. P value of <0.05 was considered significant. There were 46 patients who underwent neuronavigation guided biopsy over the period of two years. Median age of patients was 46.5 years. Supratentorial tumors accounted for 95.8% of cases. Mean tumor diameter was 3.35 cm. Accuracy was 89.1%. More than half were glial tumors. Histopathology was inconclusive in 10.9% cases. Complication rate was 4.3%: one tract hematoma and one new neurological deficit. Frameless neuronavigation guided biopsy of intracranial space occupying lesion is safe and efficacious procedure with high diagnostic yield.

scholarly journals Assessment of trace metal alterations in the blood, cerebrospinal fluid and tissue samples of patients with malignant brain tumors

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Aleksandar Stojsavljević ◽  
Ljiljana Vujotić ◽  
Branislav Rovčanin ◽  
Slavica Borković-Mitić ◽  
Marija Gavrović-Jankulović ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Trace Metal ◽  
Tissue Samples ◽  
Malignant Brain Tumors

Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

1984 ◽  
Vol 2 (5) ◽  
pp. 432-437 ◽  
Author(s):  
U Tirelli ◽  
M D'Incalci ◽  
R Canetta ◽  
S Tumolo ◽  
G Franchin ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumors ◽  
Median Survival ◽  
Stable Disease ◽  
High Performance ◽  
Clinical Symptoms ◽  
Early Death ◽  
High Performance Liquid Chromatographic ◽  
Malignant Brain Tumors ◽  
Liquid Chromatographic

Twenty-two consecutive patients with recurrent malignant brain tumors after radiation therapy and systemic combination chemotherapy with BCNU and vincristine, four of whom were not evaluable due to early death, were treated with etoposide (VP-16-213) (50-100 mg/m2 for five days every three weeks). Response, defined as improvement in both clinical examination and computed tomography scan in absence of glucocorticoids dosage increase, was observed in three (17%) of 18 evaluable patients, lasting greater than 21, seven, and two months, respectively. Six additional patients had stable disease for greater than 10, seven, four, four, three, and two months: all of them had improvement of clinical symptoms but no variation in their scans. Overall median survival from the start of VP-16-213 was 4.5 months (range, 1-23 + months), whereas patients with response or stable disease had a median survival of eight months. Overall, treatment was well tolerated. In 10 patients concomitant plasma and cerebrospinal fluid samples were evaluated with a high-performance liquid chromatographic method for drug assay. The concentration of VP-16-213 in cerebrospinal fluid was less than 1% that found in plasma, even in the two patients with response. The activity of etoposide in patients with malignant, lomustine-vincristine-resistant brain tumors suggests an interesting potential use for this drug.

scholarly journals Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1546 ◽  
Author(s):  
Alena Kopkova ◽  
Jiri Sana ◽  
Tana Machackova ◽  
Marek Vecera ◽  
Lenka Radova ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Low Grade ◽  
Tumor Type ◽  
Tumor Patients ◽  
Primary Tumors ◽  
Mirna Profiling ◽  
Tumor Types ◽  
Cns Malignancies

Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.

scholarly journals GENE-03. SPECIFIC SIGNATURES OF microRNA IN CEREBROSPINAL FLUID OF PATIENTS WITH PRIMARY BRAIN TUMORS AND METASTASES

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi98-vi98
Author(s):  
Radim Jancalek ◽  
Martin Smrcka ◽  
Alena Kopkova ◽  
Jiri Sana ◽  
Marek Vecera ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Czech Republic ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Brain Metastases ◽  
Independent Set ◽  
Low Grade ◽  
Primary Brain Tumors ◽  
Csf Analysis ◽  
Different Levels

Abstract Cerebrospinal fluid (CSF) baths extracellular environment of the central nervous system, and thus, it is ideal source of tumor diagnostic biomarkers like microRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers. As dysregulated levels of brain tumor specific miRNAs have been already observed in CSF, analysis of CSF miRNAs in brain tumor patients might help to develop new diagnostic platform. Next-Generation sequencing (NGS) was performed for analysis of small RNAs in 89 CSF samples taken from 32 glioblastomas (GBM), 14 low-grade gliomas (LGG), 11 meningiomas, 13 brain metastases and 19 non-tumor donors. Subsequently, according to NGS results levels of 10 miRNAs were measured in independent set of CSF samples (41 GBM, 44 meningiomas, 12 brain metastases and 20 non-tumor donors) using TaqMan Advanced miRNA Assays. NGS analysis revealed 22, 12 and 35 CSF miRNAs with significantly different levels in GBM, meningiomas, and brain metastases (adj.p < 0.0005, adj.p < 0.01, and adj.p < 0.005) respectively, in comparison with non-tumor CSF samples. Subsequent validation of selected CSF miRNAs has confirmed different levels of 7 miRNAs in GBM, 2 in meningiomas, and 2 in brain metastases compared to non-tumors. Panel of miR-30e-5p and miR-140-5p was able to distinguish brain metastases with 65% sensitivity and 100% specificity compared to non-tumor samples (AUC = 0.8167); panel of miR-21-3p and miR-196-5p classified metastatic patients with 78% sensitivity and 92 % specificity in comparison to GBM (AUC = 0.90854) and with 75% sensitivity and 83% specificity compared to meningiomas (AUC = 0.84848). We have observed that CSFs from patients with various primary brain tumors and metastases are characterized by specific miRNA signatures. This work was supported by the Ministry of Health, Czech Republic grant nr. NV18-03-00398 and the Ministry of Education, Youth and Sports, Czech Republic under the project CEITEC 2020 (LQ1601).

Sign in / Sign up

Export Citation Format

Share Document